ÂÜÀòÂÒÂ×

Mr. Schroeder is currently Chief Executive Officer and a director of Nabriva Pharmaceuticals, a role he has held subsequent to the 2018 acquisition of Zavante Therapeutics,a company that he co-founded and served as President, Chief Executive Officer and a member of the Board of Directors. Prior to that,he was one of Cadence Pharmaceutical’s co-founders and served as President, Chief Executive Officer and a Board of Director’s member since its inception in May 2004 until its acquisition by Mallinckrodt Pharmaceuticals for $1.4billionin 2014. From August 2002 to February 2004, he served as Senior Vice President of North America Sales and Marketing of Elan Pharmaceuticals, Inc., a neuroscience-based pharmaceutical company. From February 2001 to August 2002, Mr. Schroeder served as General Manager of the Hospital Products Business Unit at Elan, a position he also held at Dura Pharmaceuticals, Inc., a specialty respiratory pharmaceutical and pulmonary drug delivery company, from May 1999 to November 2000 until its acquisition by Elan. Prior to joining Dura, Mr. Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb Company, a global

pharmaceutical company. Mr. Schroeder is the former Chairman of Biocom, a regional life science trade association. Mr. Schroeder is also a current director of Otonomy, Inc.and Collegium Pharmaceutical. Previously Mr. Schroeder served on the boards of Cadence Pharmaceuticals, Incline Therapeutics, Hyperion Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder holds a B.S. in Management from Rutgers University.